证券之星消息，截至2026年1月29日收盘，可孚医疗(301087)报收于53.06元，下跌0.41%，换手率 1.35%，成交量2.63万手，成交额1.41亿元。 1月29日的资金流向数据方面，主力资金净流出392.38万元，占总成交额2.79%，游资资金净流入 1539.41万元，占总成交额10.93%，散户资金净流出1147.03万元，占总成交额8.14%。 近5日资金流向一览见下表： 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 可孚医疗2025年三季报显示，前三季 ...

可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 证券之星消息，截至2026年1月27日收盘，可孚医疗(301087)报收于54.88元，下跌1.08%，换手率 1.51%，成交量2.93万手，成交额1.6亿元。 1月27日的资金流向数据方面，主力资金净流出150.77万元，占总成交额0.94%，游资资金净流出653.33 万元，占总成交额4.09%，散户资金净流入804.1万元，占总成交额5.03%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家 ...

证券之星消息，截至2026年1月26日收盘，可孚医疗(301087)报收于55.48元，下跌1.72%，换手率 1.74%，成交量3.38万手，成交额1.86亿元。 1月26日的资金流向数据方面，主力资金净流出734.45万元，占总成交额3.94%，游资资金净流入184.32 万元，占总成交额0.99%，散户资金净流入550.13万元，占总成交额2.95%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), indicating a slight decline in stock price and mixed capital flow on January 22, 2026 [1] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.63%, with a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter revenue of 902 million yuan, representing a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, up 38.68% year-on-year [2] Group 2 - The company has a debt ratio of 27.37% and reported investment income of 18.18 million yuan, with financial expenses recorded at -3.77 million yuan, indicating a healthy financial position [2] - The gross profit margin for Kefu Medical stands at 53.35%, showcasing strong profitability within its industry [2] - Over the past 90 days, 8 institutions have provided ratings for the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 54.56 yuan [2]

Company Overview - Kewei Medical Technology Co., Ltd. is located in Changsha, Hunan Province, and was established on November 19, 2009. The company went public on October 25, 2021. Its main business involves the research, production, sales, and service of home medical devices [1]. Business Segmentation - The revenue composition of Kewei Medical is as follows: rehabilitation aids account for 43.12%, medical care products 32.45%, health monitoring products 20.76%, and other supplementary products 3.68% [1]. Stock Performance - On January 20, Kewei Medical's stock fell by 5.02%, trading at 54.83 yuan per share, with a transaction volume of 225 million yuan and a turnover rate of 2.07%. The total market capitalization is 11.454 billion yuan [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Xingyin Fund holds Kewei Medical shares. The Xingyin Smart Consumer Mixed A Fund (018990) held 83,800 shares in the third quarter, accounting for 4.1% of the fund's net value, making it the fifth-largest holding. The estimated floating loss today is approximately 243,000 yuan [2]. Fund Performance - The Xingyin Smart Consumer Mixed A Fund (018990) was established on November 2, 2023, with a latest scale of 19.7561 million yuan. Year-to-date returns are 4.29%, ranking 4830 out of 8848 in its category. Over the past year, the return is 32.78%, ranking 3911 out of 8093. Since inception, the return is 31.97% [2]. Fund Management - The fund manager of Xingyin Smart Consumer Mixed A is Qiao Huaguo, who has been in the position for 2 years and 74 days. The total asset size of the fund is 335 million yuan, with the best return during his tenure being 60.73% and the worst being 1.46% [3].

Group 1 - The core viewpoint of the article highlights the performance and financial metrics of Kefu Medical (301087) as of January 19, 2026, with a closing price of 57.73 yuan, reflecting a 1.58% increase [1] - Kefu Medical's main business involves the research, production, sales, and service of home medical devices [2] - The company reported a total revenue of 2.398 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders for the same period was 260 million yuan, up 3.3% year-on-year, while the net profit excluding non-recurring items was 222 million yuan, increasing by 1.46% [2] - In Q3 2025, Kefu Medical achieved a quarterly revenue of 902 million yuan, marking a significant year-on-year growth of 30.72% [2] - The company's Q3 net profit attributable to shareholders was approximately 92.83 million yuan, reflecting a 38.68% increase year-on-year, and the net profit excluding non-recurring items was about 85.80 million yuan, up 62.68% [2] - Kefu Medical's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan, while the gross profit margin is reported at 53.35% [2] Group 2 - Over the past 90 days, 8 institutions have provided ratings for Kefu Medical, with 7 buy ratings and 1 hold rating [2] - The average target price set by institutions for Kefu Medical over the last 90 days is 54.56 yuan [2] - On January 19, 2026, the net outflow of main funds was 317,800 yuan, accounting for 0.12% of the total transaction amount, while retail investors experienced a net outflow of 1.33 million yuan, representing 4.87% of the total transaction amount [1]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), including stock price movement and trading volume [1][2] - As of January 16, 2026, Kefu Medical's stock closed at 56.83 yuan, down 2.27%, with a turnover rate of 2.5% and a trading volume of 48,600 lots, amounting to a total transaction value of 279 million yuan [1] - The net capital outflow from major funds was 36.34 million yuan, accounting for 13.03% of the total transaction value, while retail investors saw a net inflow of 52.52 million yuan, representing 18.82% of the total transaction value [1] Group 2 - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is a 38.68% increase year-on-year [2] - The company's debt ratio stands at 27.37%, with an investment income of 18.18 million yuan and a financial expense of -3.77 million yuan, while maintaining a gross profit margin of 53.35% [2] Group 3 - Over the past 90 days, eight institutions have provided ratings for Kefu Medical, with seven giving a "buy" rating and one an "increase" rating, while the average target price set by institutions is 54.56 yuan [2]

Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight decline, with a closing price of 59.5 yuan on January 14, 2026, down by 1.65% [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year [2] - The net profit attributable to the parent company was 260 million yuan, up by 3.3% year-on-year [2] - The net profit after deducting non-recurring items was 222 million yuan, reflecting a year-on-year increase of 1.46% [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, a significant increase of 30.72% year-on-year [2] - The single-quarter net profit attributable to the parent company was approximately 92.83 million yuan, up by 38.68% year-on-year [2] - The single-quarter net profit after deducting non-recurring items was 85.80 million yuan, marking a year-on-year increase of 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan [2] - The gross profit margin is reported at 53.35% [2] Market Activity - On January 14, 2026, the net outflow of main funds was 23.53 million yuan, accounting for 3.54% of the total transaction amount [1] - Retail investors saw a net inflow of 17.96 million yuan, representing 2.7% of the total transaction amount [1] - Over the past 90 days, 8 institutions have provided ratings for Kefu Medical, with 7 buy ratings and 1 hold rating [2] - The average target price set by institutions in the last 90 days is 545.6 million yuan [2]

Group 1 - The core viewpoint of the news is that Kefu Medical (301087) has shown a positive performance in both stock price and financial results, indicating potential growth in the home medical device sector [1][2]. - As of January 12, 2026, Kefu Medical's stock closed at 59.3 yuan, up 6.69%, with a turnover rate of 6.39% and a trading volume of 124,100 hands, resulting in a transaction amount of 720 million yuan [1]. - The net inflow of main funds on January 12 was 80.17 million yuan, accounting for 11.13% of the total transaction amount, while retail investors experienced a net outflow of 54.67 million yuan, representing 7.59% of the total transaction amount [1]. Group 2 - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, reflecting a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is a 38.68% increase year-on-year [2]. - The company has a debt ratio of 27.37%, with investment income of 18.18 million yuan and a gross profit margin of 53.35% [2].

Group 1 - The core viewpoint of the news is that Kefu Medical has seen a stock price increase of 5.24%, reaching 58.49 CNY per share, with a trading volume of 2.12 billion CNY and a market capitalization of 12.218 billion CNY as of January 12 [1] - Kefu Medical, established on November 19, 2009, and listed on October 25, 2021, is primarily engaged in the research, production, sales, and service of home medical devices [1] - The revenue composition of Kefu Medical includes rehabilitation aids at 43.12%, medical care products at 32.45%, health monitoring products at 20.76%, and other supplementary products at 3.68% [1] Group 2 - From the perspective of fund holdings, Kefu Medical is a significant investment for the Xingyin Fund, with the Xingyin Smart Consumer Mixed A Fund (018990) holding 83,800 shares, accounting for 4.1% of the fund's net value, making it the fifth-largest holding [2] - The Xingyin Smart Consumer Mixed A Fund was established on November 2, 2023, with a latest scale of 19.7561 million CNY, and has achieved a year-to-date return of 3.07% [2] - The fund has a one-year return of 32.34%, ranking 3994 out of 8157 in its category, and a cumulative return since inception of 30.42% [2]